Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 130 | 25 | 104 |
| Samples | 119 | 19 | 99 |
| Peptides | 87 | 13 | 76 |
Function
KRTAP5-9 · Keratin associated protein 5-9
Enables identical protein binding activity. Predicted to be involved in epidermis development. Predicted to be located in cytosol. [provided by Alliance of Genome Resources, Apr 2022]
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000528743 | P26371 | 130 | 87 |
Gene Properties
Recurrent Mutations
All 87 amino-acid changes on canonical ENST00000528743 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in KRTAP5-9 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in KRTAP5-9 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Endometrial Carcinoma | 0/42 0% | 7/612 1% |
| Cervical Carcinoma | 0/35 0% | 4/422 1% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 11/1592 1% |
| Melanoma | 2/210 1% | 11/1899 1% |
| Non-Small Cell Lung Carcinoma | 6/304 2% | 2/1390 0% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Neuroendocrine Tumour | 1/154 1% | 2/577 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 3/752 0% |
| Esophageal Carcinoma | 0/23 0% | 3/769 0% |
| Colorectal Carcinoma | 1/143 1% | 11/3239 0% |
| Hepatocellular Carcinoma | 0/46 0% | 8/2210 0% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 6/2550 0% |
| Other Solid Cancers | 0/94 0% | 5/1515 0% |
| Bladder Carcinoma | 0/58 0% | 3/956 0% |
| Plasma Cell Myeloma | 1/44 2% | 0/305 0% |
| Gastric Carcinoma | 0/74 0% | 5/1809 0% |
| Neuroblastoma | 0/87 0% | 2/1331 0% |
| Prostate Carcinoma | 0/13 0% | 3/2105 0% |
| Pancreatic Carcinoma | 0/89 0% | 2/1611 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 1/810 0% |
| Other Blood Cancers | 1/61 2% | 2/2725 0% |
| B-Lymphoblastic Leukemia | 2/55 4% | 1/2640 0% |
| Non-Cancerous | 0/104 0% | 1/830 0% |
| Ovarian Carcinoma | 0/109 0% | 1/998 0% |
| Head and Neck Carcinoma | 0/85 0% | 1/1574 0% |
| Glioma | 0/52 0% | 1/2127 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 1/2534 0% |
Mutation Distribution
Where KRTAP5-9 is mutated · all tissues, split by cell line vs tissue
How many mutations in KRTAP5-9 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 130 mutations in KRTAP5-9
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|